ClinicalTrials.gg
RecruitingNCT04529967Updated May 15, 2026

Child-Parent Familial Hypercholesterolemia Screening

An observational study in Familial Hypercholesterolemia, sponsored by Children's Hospital of Fudan University. Recruiting at 6 sites in China. Open to participants aged 1 Year to 3 Years. Per ClinicalTrials.gov, last updated 2026-05-15.

Sponsored by Children's Hospital of Fudan University · Observational

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Family-based
Time perspective
Cross-sectional
Enrollment
15,000
Ages
1 Year to 3 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Hyperlipoproteinemia Type II with a site in China — 13 open to participants now, 13 under way, 7 of them phase 3. Hyperlipoproteinemia Type II · China.

Started
2025
with 2 others
Observational
2 of 24
1 open now
Primary completion
2026-09
later than 3 of 12 live
Registered
4th of 24
by date
Lead sponsor
1 of 24
Children's Hospital of Fudan University

Among the 24 studies in Hyperlipoproteinemia Type II with a site in China, this one is one of 3 that started in 2025, is one of 2 observational ones, reaches primary completion later than 3 of the 12 other live ones, and was the 4th registered.

Hyperlipoproteinemia Type II

251 studies on the registry are indexed under Hyperlipoproteinemia Type II; 57 are open to participants now.

Browse Hyperlipoproteinemia Type II studies →

Open to participants now

13 of the 24 studies in Hyperlipoproteinemia Type II with a site in China are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 37 Hyperlipoproteinemia Type II studies recruiting now, 17 (46%) set no upper age limit and 16 (43%) stop at 75 or younger; 17 take children under 18; 6 take healthy volunteers.

This study: 1 Year to 3 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Hyperlipoproteinemia Type II with a site in China, or all of them as a file.
02

Study summary

Child-parent screening for familial hypercholesterolemia has been proposed to identify children and their parent who are carrier of mutations and with high risk for inherited premature coronary artery disease. The investigators assessed the efficacy and feasibility of such screening in primary care practice.

key scientific questions:

  1. The 95th and 99th percentile of finger blood TC in children of 2 years old.
  2. Mutations that contribute to high TC status ( serum TC >99th percentiles) compared with international FH48 panel for FH genetic screening.
Read the detailed description

Familial hypercholesterolemia (FH) is an inherited condition resulting in high levels of low-density lipoprotein cholesterol (LDL-C) and increased risk of premature coronary artery disease in men and women. Child-parent screening for familial hypercholesterolemia has been proposed to identify persons who are carriers of FH mutations and with high risk for inherited premature coronary artery disease. The investigators will conduct a cross-sectional community-based screening in children of 2 years old to detect FH children cases using finger blood TC test first and followed by serum TC test and mutation test, and to identify and diagnose their affected parents. This study aims to established the child-parent screening program and technique issues for early diagnosis of familial hypercholesterolemia families for future early intervention.

Child-parent screening strategy in our study consists three steps: i. Capillary blood total cholesterol test of children aged around 2 years; ii. re-test for children with cholesterol>95th percentile in the first step; iii. WES (whole exome sequencing) test for >P99 in the first two steps. iV: TC test and mutation test to the parents of the child FH cases. The investigators will determine FH families based on the program. Children's Hospital of Fudan University will provide treatment further.

03

Conditions studied

  • Familial Hypercholesterolemia
04

Who can participate

Ages eligible
1 Year to 3 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All community-children from slelected communities aged 1 to 3 who receive regular child care (programmed immunization vaccination clinic) within a prespecified study period

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Receive routine child care
  • aged 1 - 3 years old ( date of investigate minus date of birth)

Exclusion criteria

Exclusion Criteria:

  • It is up to the researcher to decide whether it is suitable to participate in this research
05

Study design

Observational model
Family-based
Time perspective
Cross-sectional
Enrollment
15,000 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes
Biospecimen retention
Samples with dna

Interventions

  • Otherno interventions

    it is a observational study, do not have interventions.

06

What researchers measure

Primary outcomes

  1. The affected status of Familial Hypercholesterolemia

    heterozygote or homozygote carriers of established FH mutations in LDLR, PSCK9 and APOB gene, including mutations included in the FH48 and new ones identified in Chinese children

    Time frame: At enrollment

Secondary outcomes

  1. fasting total cholesterol level by Fingertip capillary blood test in children around 2 years old

    Time frame: At enrollment

  2. affected status of known FH mutation

    according to FH48

    Time frame: At enrollment

  3. fasting serum LDL-c levels of children with finger TC over P95

    Time frame: At enrollment

07

Study locations

6 of 6 sites recruiting
  • Anhui Provincial Children's Hospital
    Hefei, Anhui, China
    Recruiting
    • Haipeng Liu · Contact
  • Qidong Women and Children Hospital
    Qidong, Jiangsu, China
    Recruiting
    • Jun Shen · Contact
  • Weili Yan
    Shanghai, Shanghai Municipality 201102, China
    Recruiting
    • YI Zhang, PhD · Contact
  • Shanxi Provincial Children's Hospital
    Taiyuan, Shanxi, China
    Recruiting
    • Lixia Bai · Contact
  • Chongqin Medical University Affiliated Children's Hospital
    Chongqing, Sichuan, China
    Recruiting
    • Xiaohua Liang · Contact
  • Urumqi Children's Hospital
    Ürümqi, Xinjiang 830000, China
    Recruiting
    • Wenping Cai · Contact
08

References and documents

Individual participant data

Plan to share: Undecided — The data generated and/or during current study are not publicly available due to incomplete study, but are available from the corresponding author on reasonable request.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2025 (actual). Primary completion is estimated for Sep 2026, 17 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2020
First posted
Aug 28, 2020
StartActual
Apr 1, 2025
Primary completionEst.
Sep 30, 2026
CompletionEst.
Sep 30, 2026
Last update
May 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04529967
Responsible party
Sponsor
First posted
Aug 28, 2020
Start date
Apr 1, 2025
Primary completion
Sep 30, 2026 (estimated)
Completion
Sep 30, 2026 (estimated)
Last update
May 15, 2026

Study contacts

Weili Yan
Contact
yanwl@fudan.edu.cn
+86 21 64931215
Fang Liu, MD
Contact
liufang@fudan.edu.cn
LIling Qian, Master
study director · Children's Hospital of Fudan University
Rui Dong, MD
study director · Children's Hospital of Fudan University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion